Skip to content
Open menu Close menu

Professor Laurence Patterson

PositionProfessor of Drug Discovery
DepartmentInstitute of Cancer Therapeutics
Telephone+44 (0) 1274 233226
EmailL.H.Patterson@bradford.ac.uk
LinkedInVisit my LinkedIn profile

Research Interests (key words only)

Tumour-selective drug activation The glycocalyx as a target for drug discovery Modulators of integrin activity Inhibitors of chemokines Bioreductive activation of drugs in hypoxia tumours Cytochromes P450 in tumours

Administrative Responsibilities


 

Study History

PhD (London)

BSc Hons (Hertfordshire)

Professional Activities

   Director of the Institute of Cancer Therapeutics
    Founder of Incanthera Ltd (www.incanthera.com) university spin out supporting ICT drug discovery portfolio
    Founder and on Management Board of Ethical Tissue, human tissue bank (www.ethicaltissue.org)
    Founding Director of Biostatus Ltd (www.Biostatus.com)
    Director of PKPD Inc (www.pkpdinc.com)

Research Areas

Postgraduate Student Supervision

  • Fatemah Al-Shammari (joint supervision with Dr Helen Sheldrake and Dr Steve Shnyder)
  • Hanadi Ahmedah (joint supervision with Dr Helen Sheldrake and Dr Steve Shnyder)
  • Manar Saleh Zraikat (joint supervisioon with Dr Helen Sheldrake, Dr Steve Shnyder and Dr Roger Phillips)
  • Abdulaziz Bin Saeedan (joint supervision with Dr Steve Shnyder and Dr Paul Loadman)
  • Adam Throup (joint supervision with Dr Helen Sheldrake)

Current Projects

Principle Investigator: Cancer Medicines Discovery Programme Grant, Yorkshire Cancer Research
Co-Investigator: EPSRC/MRC Bradford University-China Bridge Award Science Bridges poster (pdf, 570KB)
Co-applicant Experimental Cancer Medicines Centre (Leeds, Bradford)

Networks/Roles

Professional Society Memberships and Positions of Esteem

    Honorary member of the Royal Pharmaceutical Society of Great Britain
    Elected Fellow of the Royal Society of Chemistry
    Guest Professor in Drug Discovery, TMMU, Chongqing, China
    Honorary Professor in Drug Discovery, Southwestern University, Chongqing, China
    British Association of Cancer Research
    American Association for Cancer Research
    Athenaeum (Pall Mall)
    Member and panel member of the EPSRC peer review college
    Guest Editor for Current Topics in Pharmaceutical Design
    International Editor Acta Academiae Medicinae Militaris Tertiae
    RSC Team Innovation Award recipient 2012

Publications

Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res. 2013 Apr 15. [Epub ahead of print] PubMed PMID: 23589180

Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1. PubMed PMID: 23033491

Falconer RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH. Polysialyltransferase: a new target in metastatic cancer. Curr Cancer Drug Targets. 2012 Oct;12(8):925-39. Review. PubMed PMID: 22463390

McMahon KM, Volpato M, Chi HY, Musiwaro P, Poterlowicz K, Peng Y, Scally AJ, Patterson LH, Phillips RM, Sutton CW. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. J Proteome Res. 2012 May 4;11(5):2863-75. doi: 10.1021/pr2012472. Epub 2012 Mar 30. PubMed PMID: 22416669

Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14. PubMed PMID: 22002321

Veiga J.P., Cooper P.A., Pors K, Patterson L.H., Bibby M.C., Shnyder S.D. Use of the hollow fiber assay for the evaluation of DNA damaging agents. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. Epub 2011 Apr 30. PubMed PMID: 21569858

Vinader V, Al-Saraireh Y, Wiggins H.L., Rappoport J.Z., Shnyder S.D., Patterson L.H., Afarinkia K. An agarose spot chemotaxis assay for chemokine receptor antagonists. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):213-6. Epub 2011 Feb 1. PubMed PMID: 21292017

Atkinson J.M., Falconer R.A., Edwards D.R., Pennington C.J., Siller C.S., Shnyder S.D., Bibby M.C., Patterson L.H., Loadman P.M., Gill J.H. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010 Sep 1;70(17):6902-12. Epub 2010 Jul 27 PubMed PMID: 20663911; PubMed Central PMCID: PMC2933508

Sutton C.W., Sutherland M, Shnyder S, Patterson L.H. Improved preparation and detection of cytochrome P450 isoforms using MS methods. Proteomics. 2010 Jan;10(2):327-31. PubMed PMID: 19902426

Seibert C, Davidson B.R., Fuller B.J., Patterson L.H., Griffiths W.J., Wang Y. Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. J Proteome Res. 2009 Apr;8(4):1672-81. PubMed PMID: 19714871; PubMed Central PMCID: PMC2939981

Sheldrake H.M., Patterson L.H. Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets. 2009 Jun;9(4):519-40. Review. PubMed PMID: 19519320

Abdallah Q.M., Phillips R.M., Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse R.T., Kiakos K, Bingham J.P., Hartley J.A., Patterson L.H., Pors K. Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. Epub 2012 Mar 1. PubMed PMID: 22387433

Share this